World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
97
Citations
45287
World Ranking
9128
National Ranking
315

Dino Amadori publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dino Amadori sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 749 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Dino Amadori D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dino Amadori sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 97 D-Index — 55th percentile

55% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Dino Amadori is affiliated with the University of Bologna in Italy and has conducted extensive research in the field of medicine, with a primary focus on oncology. Their scholarly output includes 28 publications in medicine, of which 14 are specifically related to oncology. Additional subfields of study include pulmonary and respiratory medicine, cancer research, radiology, nuclear medicine and imaging, and molecular biology.

Their recent papers demonstrate a focus on breast cancer and multiple myeloma research. Notable publications include:

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study (2020) published in The Lancet Oncology
  • A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) (2021) published in Breast Cancer Research and Treatment
  • Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study (2020) published in The Lancet Haematology
  • Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial (2020) published in Breast Cancer Research and Treatment
  • Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer (2021) published in Therapeutic Advances in Medical Oncology

Frequent co-authors who have collaborated with Amadori include Oriana Nanni, Andrea Rocca, Lorenzo Gianni, Carlo Milandri, and Giovanni Luca Frassineti. These collaborations have supported a range of studies mainly focused on cancer therapies and clinical outcomes.

Their work has been published in a number of scientific venues, with Therapeutic Advances in Medical Oncology and Breast Cancer Research and Treatment being the most frequent outlets. Other publication venues include The Lancet Oncology, The Lancet Haematology, and Molecular Oncology.

Research topics covered by Dino Amadori include:

  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Cells and Metastasis
  • Gastric Cancer Management and Outcomes
  • Breast Cancer Treatment Studies
  • Colorectal Cancer Treatments and Studies
  • Global Cancer Incidence and Screening

Amadori has also authored a book titled CLASSE HOSPITALAR, ATENDIMENTO PEDAGÓGICO DOMICILIAR E BRINQUEDOTECA HOSPITALAR, scheduled for publication in 2025 by Editora Schreiben eBooks.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Lawrence Schwartz;Sergio Ricci;Dino Amadori

  • The Global Breast Cancer Burden: Variations in Epidemiology and Survival

    Gabriel N. Hortobagyi;Jaime de la Garza Salazar;Kathleen Pritchard;Dino Amadori

  • Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization

    Manav Korpal;Brian J Ell;Francesca M Buffa;Toni Ibrahim

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • A case-control study of gastric cancer and diet in Italy.

    Eva Buiatti;Domenico Palli;Adriano Decarli;Dino Amadori

  • Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial

    Francesco Boccardo;Alessandra Rubagotti;Matteo Puntoni;Pamela Guglielmini

  • A New Palliative Prognostic Score: A First Step for the Staging of Terminally Ill Cancer Patients

    Marco Pirovano;Marco Maltoni;Oriana Nanni;Mauro Marinari

  • Successful Validation of the Palliative Prognostic Score in Terminally Ill Cancer Patients

    Marco Maltoni;Oriana Nanni;Marco Pirovano;Emanuela Scarpi

  • Modulation of mismatch repair and genomic stability by miR-155

    Nicola Valeri;Pierluigi Gasparini;Muller Fabbri;Chiara Braconi

  • Plasma AR and abiraterone-resistant prostate cancer.

    Alessandro Romanel;Delila Gasi Tandefelt;Vincenza Conteduca;Anuradha Jayaram;Anuradha Jayaram

  • MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2)

    Nicola Valeri;Pierluigi Gasparini;Chiara Braconi;Alessio Paone

  • Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

    Luigi Dogliotti;Giacomo Cartenì;Salvatore Siena;Oscar Bertetto

  • miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis

    Yun Zhang;Pengyuan Yang;Pengyuan Yang;Tao Sun;Dong Li

  • Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy

    Kishore B. Challagundla;Petra M. Wise;Paolo Neviani;Haritha Chava

  • Association of a microRNA/TP53 Feedback Circuitry With Pathogenesis and Outcome of B-cell Chronic Lymphocytic Leukemia

    Muller Fabbri;Arianna Bottoni;Masayoshi Shimizu;Riccardo Spizzo

  • Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

    F Roila;M Tonato;F Cognetti;E Cortesi

  • Palliative Sedation in End-of-Life Care and Survival: A Systematic Review

    Marco Maltoni;Emanuela Scarpi;Marta Rosati;Stefania Derni

  • Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2

    Rumela Chakrabarti;Rumela Chakrabarti;Julie Hwang;Mario Andres Blanco;Yong Wei

  • A case-control study of gastric cancer and diet in Italy: II. Association with nutrients

    Eva Buiatti;Domenico Palli;Adriano Decarli;Dino Amadori

Frequent Co-Authors

Ugo De Giorgi
Ugo De Giorgi University of Salento
Paolo Bruzzi
Paolo Bruzzi Ospedale San Martino
Pierfranco Conte
Pierfranco Conte University of Padua
Angelo Paradiso
Angelo Paradiso National Cancer Research Institute, UK
Yibin Kang
Yibin Kang Princeton University
Domenico Palli
Domenico Palli Institute for the Study and Prevention of Cancer (Istituto per lo Studio, la Prevenzione e la Rete Oncologica)
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University
Adriano Decarli
Adriano Decarli University of Milan
Armando Santoro
Armando Santoro Humanitas University
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond a traditional MD pathway, there are many alternative and complementary online degrees that can accelerate your career in medicine or healthcare. Whether you’re seeking advanced practice roles or looking to build foundational clinical skills, online programs can offer flexibility, speed, and affordability.

For registered nurses aiming to move quickly into leadership or specialized clinical positions, exploring short DNP programs can be an effective route. These accelerated programs help qualified nurses attain a Doctor of Nursing Practice degree in less time than traditional options.

Budget is another major consideration. If you’re concerned about costs, it’s worth looking at a cheapest DNP program that delivers both value and quality education without a financial burden.

For those starting out in nursing, LPN programs offer a fast entry into the workforce through short, practical coursework, setting you up for direct patient care in under a year.

Mental health is another expanding field. Nurses considering a specialization should explore the fastest psych NP program to obtain credentials as a psychiatric nurse practitioner via online study.

These varied online options provide flexible pathways to expand your career opportunities in today’s competitive healthcare landscape.

Best Scientists Citing Dino Amadori

Trending Scientists

Recently Published Articles